We present development and human application of a method for determining the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron emission tomography (PET) and [ "C] dihydrotetrabenazine (DTBZ). Previous animal studies indicate striatal W T 2 density is linearly related to the integrity of substantia nigra dopamine neurons and is not subject to drug-or lesion-compensatory regulation. In the present studies, kinetic compartmental modeling was employed to estimate blood-brain ["CIDTBZ transport (lir,) and Vh4AT2 binding site density (tissue-to-plasma DTBZ distribution volume, DV) from the cerebral and plasma DTBZ time courses h e r intravenous tracer injection. In controls, we found reductions of putamen DTBZ DVwith advancing age, corresponding to losses of 0.77% per year in specific VMAT2 binding. Parkinson's disease (PD) patients had reduction in specific DTBZ DV in the putamen (-61%) and in the caudate nucleus (-43%). There was no overlap of lowest specific putamen DTBZ DVbetween individual elderly controls and PD patients. The present results indicate the suitability of ["CIDTBZ PET for objective quantification of nigrostriatal integrity, including evaluation of PD progression and its possible therapeutic modification.
PD, are unknown. Effects of environmental toxins [5, 61, genetic predisposition [7] , oxidative stress [S, 91, and even differing symptomatic therapies [lo, 111 on the development and progression of PD have been proposed. An objective, noninvasive marker of nigrostriatal pathology would be helpful to advance our current understanding of PD and to permit direct testing of these hypotheses.
Several radiotracers have been employed previously to image nigrostriatal terminals and the changes in P D in vivo, including ["F] AuoroDOPA (FDOPA) [12] , ["Clnomifensine [13] , ["CJWIN 35, 428 [14] , and [I2'I] P-CIT [ 1 51 . Unfortunately, the processes revealed by these ligands are subject to drug-induced and disease-compensatory regulation, limiting their abilities to quantify accurately PD lesion severity [ 161. In the present studies, we introduce the novel ligand ["Cldihydrotetrabenazine ([ "CIDTBZ) for in vivo binding estimates of the type 2 vesicular monoamine transporter (VMAT2) in the human brain. Prior studies of this presynaptic monoaminergic binding site in experimental animals indicate that it is not regulated readily by conditions that alter the synthesis, turnover, or release of dopamine [17, 181. Further, its striatal concentration is highly correlated with the number of intact nigral dopaminergic neurons following graded neurotoxin lesions [ 191, suggesting that VMAT2 density may be an objective marker of nigrostriatal terminal integrity. The current studies extend our investigations of [ [ "]DTBZ in a 225-grn male Sprague-Dawley rat, arterial blood was sampled and the rat was killed by intravenous injection of pentobarbital followed by saturated K(:l to produce cardioplegia. Plasma aliquots were analyzed by liquid scintillation spectroscopy both directly and after deproteination by the addition of 3 volumes of absolute ethanol and centrifugation at 10,000 x g for 10 min. Samples of brain and liver were homogenized in ethanol (3: 1 , volltissue weight), and aliquocs of the total homogenates and postcentrifugation supernatants were assayed to assess recovery. Additional aliquots of the ethanolic cissue and plasma supernatants were concentrated under vacu~tni and further analyzed by thin-layer chromatography (TLC) on silica gel plates (E. Merck no. 5721, Darmstadt, Germany) with a mobile phase of chloroformlmethanol 96 : 4. Chromatograins were autoradiographed by apposition to x-ray film (SB5. Eastman Kodak, Kochester, NY) at -70°C for 3 days with the use of a fluorographic enhancer (En'hance, Arnershani Corp). Labeled species identified in the autoradiograms were scraped from the TLC plates and assayed by liquid scintillation spectroscopy.
Samples of radiolabeled, polar ['HIDTBZ metabolites obtained from 1 L C of liver were employed in conjunction with authentic [ 'HIDTBZ to develop a rapid liquid chroniatographic procedure for their separation. Samples of DTBZ or labeled metabolites were applied to Whatman Sep-I'ak C,, chromarography columns (Waters Division, Millipore Corp, Milford, MA) in 1 ml of phosphate-buffered saline (PBS; NaCl 124 mM, KCI 2.7 mM, Na,HPO, 7.7 mM. KH,PO, 1.5 mM, pH 7.4) and eluted with 9 ml ethanollPBS mobile phases of varying proportion followed by 5 ml of absolute ethanol. Eluates were assayed in sequential 1-ml fractions by liquid scintillation spectroscopy to determine both elution profile and sample recovery. [21] , with symptomatic durations of illness between 3 and 10 years.
Normal subjects were receiving no centrally acting niedications, whereas the PD patients were receiving levodopa/carbidopa, aniantadine, or deprenyl; antiparkinsonian medications were not discontinued prior to ["CIDTBZ imaging. The experimental protocol was approved by The University of Michigan committees on the use of human subjects in research and on the human hie of radioisotopes, and written informed consent was obtained prior ro all procedures.
["CJDTBZ Scrlns
Carbon-1 1 -labeled, racemic (?)-DTBZ was prepared by methylation of the desriiethyl precursor as described previously [22, 231 . 'The specific activity of ["CIDTBZ was determined by high-performance liquid Chromatography and ultraiolet absorption spectrometry in conjunction with radioassay in an ionization chamber, and was routinely in the range of 500 to 1,000 Cilnimol at end-of-synthesis.
Subjects were studied in a Siemens-CTI 921 Exact toniograph, which images a 15. Dynamic sequences ofscans were next corrected for subject motion during the session on the basis ofthe fiducial scalp markers.
The locations of the beads were identified in a reference frame and all other frames in the time sequence were reoriented (6 degrees of freedom, three translational and three rotational) to bring the fiducials to rhesamecoordinates throughout the entire sequence. Anatomically configured regions of interest corresponding to the midfrontal cortex, caudate nucleus, putamen, thalamus, and cerebellum were applied to the sequence of iniages in each subject's scan. Regional boundaries were defined on summed ["CIDTBZ activity maps from 0 to 7.5 minutes after injection, and were applied in parallel to the three contiguoils axial slices that best represented the body of the thalamus (thalamus and frontal cortex), the striatuni (caudate and putamen), and the midcerebellum. Heparinized arterial blood was collected at 10-second intervals for 2 minutes, followed by additional samples at 2. 
Data Analysis and Statistics
Parametric regional determinations of DTBZ rC; and total
DVwere averaged from left and right hemispheres and assessed with one-way analysis of variance (ANOVA) (within brain region) across young, middle-aged, and elderly normal and PD patient groups. Data from regions demonstrating significant ANOVA were then examined with painvise Student's t tests for difference from the elderly controls. Additional comparisons of K; patterns were performed after expressing an individual's regional parameters relative to that of the frontal cortex and on the specific Or/: as defined above, with the use of the frontal cortex to estimate the nonsaturable total DV components. A significance threshold of p < 0.05 was employed throughout.
The possibility of age-related changes in rC; or DVwas further examined by linear regression analyses of parametric and relative parameter values. To facilitate comparisons with prior striatal aging data, apparent effects were expressed in linear (zero order) rates of change relative to extrapolated parameter values at birth (age, 0 years).
Results

Metabolites and Chromatography of ( I 1 C/o TBZ
After systemic injection in the rat, ['HIDTBZ and polar metabolites were identified in the liver and plasma, but only authentic DTBZ was recovered from the brain (Fig 1) . I n plasma, two groups of polar metabolites migrated at or near the origin o n TLC. Liver chromatograms revealed similar bands of activity and another minor band of lower polarity. After isolation of the two predominant metabolite groups from liver, preliminary liquid chromatography studies revealed Fig 3) . Total DV estimates were not significantly affected by age; however, there was a trend toward decline in striatal regions in the elderly controls. When specific DV was examined, a significant decline of 0.77% per year 6 o was revealed in the putamen (see Table 2 ; Fig 4) . Parkinson ? Disease Significant reductions in specific DTBZ DV were observed in the bilaterally averaged whole putaminal (-61%) and caudate nucleus (-43%) regions in PD compared with elderly controls (see Table 2 ). In contrast to DTBZ Or/: k; values in the PD group tended to be higher than the elderly controls, achieving statistical significance in the cerebellum (see Table 1 (Fig 5) . In each patient, the DTBZ DV was reduced to cerebral cortical levels in the posterior putamen on at least one side. In contrast, the entire putamen was well distinguished from adjacent cerebral cortex bilaterally in each elderly control.
When reductions in PD patients' putamen DVmeasures were asymmetric, the most affected putamen was that contralateral to the most affected limbs.
Discussion
Measurement of VMA T2 with [I' CJD TBZ
The present work describes development and initial clinical research application of [ "ClDTBZ for nigrostriatal nerve terminal integrity measurement. The VMAT2 marker, targeted by DTBZ, has been shown previously to possess important characteristics related to its potential utility in neurodegenerative diseases. In the central nervous system, VMAT2 is expressed exclusively by monoaminergic neurons, including those utilizing dopamine, serotonin, norepinephrine, or hista- Age, y e a r s [19] and human [30] striatum, however, the relative abundance of dopamine terminals of the nigrostriatal system renders more than 95% of the VMAT2 signal specific to this projection. [31] . A relative disadvantage of VMAT2 as an imaging target may be its wide expression in the brain, precluding the use of a reference region entirely devoid of specific binding. As indicated in the present studies, however, this may not limit use of reference regions such as the cerebral cortex or cerebellum for estimation of specific striatal binding, since the latter regions have very high relative VMAT2 levels. Nevertheless, experimental designs must guard against changes in the chosen reference region, as may be assessed by the parametric (relative to blood) total DTBZ DV.
Fig 4. Effect of normal aging on dihydrotetrabenazine (DTBZ) total distribution volume (DV). (A) Total tissue
In contrast to the relationship between nigrostriatal terminal numbers and VMAT2 sites, other presynaptic dopaminergic imaging markers identify aspects that are now appreciated to undergo compensatory regulation. Uptake of the earliest in vivo imaging marker of striatal However, as in the instance of DDC, the DAT binding site density is subject to regulation by some drug treatments that alter synaptic dopamine levels and turnover, including classes of agents used in the symptomatic treatment of PD [17, [37] [38] [39] [40] .
Because of the merits of VMAT2 as a nigrostriatal marker, we have pursued several candidate radioligands for its determination in vivo with PET. Our initial selection, ["Cltetrabenazine (["CITBZ), permitted visualization of the human striatum; however, quantification of the signal could not be achieved due to the presence and abundance of pharmacologically active, labeled metabolites, including ["CIDTBZ [41] . W e next studied the metabolically directed TBZ analogue 2-0-methyldihydrotetrabenazine (methoxytetrabenazine; MTBZ), radiolabeled in a position chosen to slow its rate of metabolism and to yield unlabeled metabolites after Odemethylation. We achieved successful quantification of human VMAT2 with ["CIMTBZ but discovered the presence of a minor labeled metabolite in rodent brain [16] . Our present studies with the TBZ metabolite DTBZ are even more encouraging.
We find no evidence for labeled metabolites of DTBZ in brain and detect only polar metabolites in blood. In addition, the synthesis of ["C] DTBZ is accomplished with higher yield and reliability than those of [ "CIMTBZ. Finally, we have recently demonstrated both in vitro [23] and in vivo [42] that the isomers of the racemic DTBZ employed here display marked differences in VMAT2 binding affinity. After chiral chromatographic resolution of the desmethyl precursor, the active isomer (+)-["CIDTBZ has now' been prepared and demonstrates almost twofold higher relative human striatal accumulation than in the present studies [42] . Thus, future studies employing (+)-DTBZ should be even more sensitive to changes in VMAT2 expression.
The Nigrostriatal System i n Aging
The present results in normal subjects indicate a significant age-associated decline in VMAT2 in the putamen. Regression analysis suggests loss of 0.77% per year of extrapolated specific DTBZ DV at birth. This estimate is in good agreement with human postmorten studies on the loss of dopaminergic neurons from the substantia nigra pars compacta, suggesting 0.5 to 0.7% per year reduction [43, 441 . Postmortem assay of human striatal VMAT2 binding indicates a comparable age-associated loss of 0.74% per year [45] . Other laboratories have reported age-associated reductions in striatal DAT binding, both in vitro [46, 471 and in vivo, the latter assessed by PET with the use of ["Clcocaine [48] Fig 6) , was also used for calculation of pixel-by-pixel estimates of and DV by a rapid, weighted integral, lookup table approach [65] where and The " in the designation of apparent rate constant k c reflects its derivation from combining all three tissue compartments.
Our initial kinetic compartmental analyses of racemic ["CIDTBZ in normal subjects indicate that the specific binding to and dissociation from VMAT2 sites in the striatum are sufficiently rapid that the binding parameters k,' and k4 cannot be precisely determined in isolation, as reported also for the resolved (+)-DTBZ isomer [66] . The total tissue Or/; estimated either from the three-compartment or the two-compartment models, reveals excellent correlation with the known distribution of VMAT2 sites. The two models lead to DV estimates that are linearly correlated with one another; however, the three-compartment configuration leads to a broader dynamic range of DVvalues and better distinguishes regions of high and low VMAT2 site density. Thus, in the present studies, group differences in DV are assessed with the threecompartment model, while the detailed distribution of DV in individual subjects is depicted on a pixel-bypixel basis with the two-compartment simplification.
